Colin Bristow
Stock Analyst at UBS
(1.77)
# 3,300
Out of 4,969 analysts
102
Total ratings
33.33%
Success rate
-9.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $112.99 | -0.88% | 4 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $582 → $553 | $396.60 | +39.44% | 15 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $55.60 | +43.88% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.32 | +50.60% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $0.96 | +3.95% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $16.64 | +2.16% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $283.85 | +12.38% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.37 | +191.97% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $4.97 | +40.99% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $24.79 | +12.95% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $84.18 | +42.55% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $141.62 | +42.64% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $3.62 | +341.99% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $563.80 | +94.93% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $18.95 | +781.27% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $737.83 | -43.08% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $4.18 | -52.15% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.38 | +657.89% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $211.86 | -31.09% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $47.50 | +57.89% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.58 | +909.71% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.12 | +75.95% | 1 | Aug 23, 2021 |
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $112.99
Upside: -0.88%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $582 → $553
Current: $396.60
Upside: +39.44%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $55.60
Upside: +43.88%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.32
Upside: +50.60%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.96
Upside: +3.95%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $16.64
Upside: +2.16%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $283.85
Upside: +12.38%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.37
Upside: +191.97%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $4.97
Upside: +40.99%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $24.79
Upside: +12.95%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $84.18
Upside: +42.55%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $141.62
Upside: +42.64%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $3.62
Upside: +341.99%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $563.80
Upside: +94.93%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $18.95
Upside: +781.27%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $737.83
Upside: -43.08%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $4.18
Upside: -52.15%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.38
Upside: +657.89%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $211.86
Upside: -31.09%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $47.50
Upside: +57.89%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.58
Upside: +909.71%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.12
Upside: +75.95%